Enterococcus faecium

Unknown Manufacturer

Generate AI report

Associated Conditions

4 associated conditions

Technical identifiers

UNII ID: 34YYS7G16P

Patents

One entry per invention. Patent families filed in the US, EP, WO and CN offices.

STRAINS AND METHODS FOR IMPROVING RUMINANT HEALTH AND/OR PERFORMANCE
EP 2370585 A4Applicant: DUPONT NUTRITION BIOSCI APSPriority: 2008
CN
EP
US
WO
8 publications
HYPERIMMUNIZED EGG PRODUCT FOR TREATING OR PREVENTING ALCOHOLIC LIVER DISEASE AND GRAFT-VERSUS-HOST DISEASE
EP 4322973 B1Applicant: PRODIGY BIOTECHPriority: 2021
CN
EP
US
WO
6 publications
NOVEL ENTEROCOCCUS FAECIUM LCM001 STRAIN, AND USE THEREOF
EP 4442805 A1Applicant: MBIOMETHERAPEUTICS CO LTDPriority: 2021
EP
US
WO
3 publications
COMPOSITE BACTERIAL AGENT AND APPLICATION THEREOF
US 20250161378 A1Applicant: HEALTH AND HAPPINESS H&H HONG KONG LTDPriority: 2023
CN
US
WO
3 publications
Compositions and methods useful for modulating immunity, enhancing vaccine efficacy, decreasing morbidity associated with chronic FHV-1 infections, and preventing or treating conjunctivitis
US 2007280964 A1Applicant: KNORR RUTHPriority: 2007
CN
US
2 publications
Enterococcus faecium bacteriophage Ent-FAP-4 and use for inhibiting Enterococcus faecium proliferation of same
US 11458177 B2Applicant: INTRON BIOTECHNOLOGY INCPriority: 2017
CN
US
2 publications
Antibacterial protein EFAL-2 having bacteriolytic ability with respect to Enterococcus faecium
US 11492378 B2Applicant: INTRON BIOTECHNOLOGY INCPriority: 2017
CN
US
2 publications
Enterococcus faecium neurotoxin (BoNT/EN) and derivatives thereof
US 12098169 B2Applicant: CHILDRENS MEDICAL CENTERPriority: 2017
CN
US
2 publications
CAPILLARY BLOOD VESSEL DISORDER INHIBITING AGENT, CAPILLARY BLOOD VESSEL DISORDER AMELIORATING AGENT, AND CAPILLARY ANGIOGENESIS ACCELERATING AGENT
EP 4082555 A4Applicant: UNIV KOBE NAT UNIV CORPPriority: 2019
CN
EP
2 publications
ENTEROCOCCUS FAECIUM, DRUG FOR PREVENTING OR TREATING TUMOR, AND APPLICATION
EP 4282950 A4Applicant: MOON GUANGZHOU BIOTECH CO LTDPriority: 2021
CN
EP
2 publications

Drugs